However, screening these populations for Fabry disease is hampered by the low sensitivity of GLA activity measurement in female patients (50% [31]–67% [32]) whereas diagnostic sequencing of the GLA gene is not feasible given the high cost (currently ca. 2,000–3,000 USD). Here, GLA is linked to Fabry disease.